Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Trial ID or NCT#
NCT02654483
Status
NOT RECRUITING
Purpose
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Official Title
A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
Eligibility Criteria
Ages Eligible for Study: Older than 13 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
- * Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus
Exclusion Criteria:
- * Chronic liver or renal disease
Investigator(s)
Albert Sean Chiou, MD, MBA
Dermatologist,
Cutaneous oncology specialist
Clinical Associate Professor, Dermatology
Contact us to find out if this trial is right for you.
Contact
Claudia Teng
725-7152
View on